我院2016年临床分离大肠埃希菌耐药表型调查分析

Abstract
Figure/Table
References (22)
Related Citation (15)

Download: PDF (0 KB) HTML (40 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To analyze the distribution of drug-resistance phenotypes of clinically isolated Escherichia coli,and to provide clinicians with laboratory data to better guide antibiotic therapy.Methods The clinical isolates of 851 Escherichia coli in the First Affiliated Hospital of Xiamen University from January to December 2016 were retrospectively analyzed.Strain identification and drug sensitivity test were conducted by BioMerieux VITEK2 Compact automatic bacterial identification and drug sensitivity analysis system.Results A total of 851 strains of Escherichia coli were clinically isolated in 2016, mainly including 425 (49.9%) strains from urine, 157 (18.4%) strains from whole blood,132 (15.5%) sterile strains from body fluid (including bile, ascites, pleural effusion, joint fluid but not cerebrospinal fluid), and 50 (5.9%) strains from sputum.There were four drug-resistant phenotypes of Tetracycline antibiotics (Tetracycline and Tegacycline), among which Tetracycline (R/I) Tegacycline (S) was the dominant phenotype.There were four drug-resistant phenotypes of Quinolone antibiotics(Ciprofloxacin and Levofloxacin) and two major phenotypes were Ciprofloxacin (R/I) Levofloxacin (R/I) and Ciprofloxacin (S) Levofloxacin (S).There were six drug-resistant phenotypes of aminoglycoside antibiotics (Gentamycin,Tobramycin and Amikacin) and two major phenotypes were Gentamycin (S) Tobramycin (S) Amikacin (S) and Gentamycin (R/I) Tobramycin (R/I) Amikacin (S).There were five drug-resistant phenotypes of β-lactam enzyme inhibitor complexes (Amoxicillin/Clavulanic Acid, Ampicillin/Sulbactam and Piperacillin/Tazobatam) and Amoxicillin/Clavulanic Acid (S) Ampicillin/Sulbactam (R/I) Piperacillin/Tazobattan (S) was the dominant phenotype.There were eleven drugresistant phenotypes of β-lactam antibiotics (Ampicillin, Cefuroxime, Ceftaxime, Ceftadime, Cefepime, Aztreonam,Imipenem and Meropenem) and two major phenotypes were Ampicillin (R/I) Cefuroxime (S) Ceftaxime (S) Ceftadime (S)Cefepime (S) Aztreonam (S) Imipenem (S) Meropenem (S) and Ampicillin (R/I) Cefuroxime (R/I) Ceftaxime (R/I) Ceftadime (S) Cefepime (S) Aztreonam (S) Imipenem (S) Meropenem (S).There were some differences in the distribution of drug-resistant phenotypes among different specimens, but the distribution of major drug-resistant phenotypes was basically consistent.The resistance rate of Escherichia coli to Tetracycline, Quinolones and aminoglycosamines was more than or close to 50%, but Escherichia coli remained highly sensitive to Tegacycline, Imipenem and Meropenem.Conclusion Escherichia coli mainly causes urinary tract infection, blood stream infection, cholecystitis and abdominal infection.The clinical prevalence of bacterial resistance phenotypes is relatively stable and the main kind of resistant pattern is relatively obvious.There are some differences in the distribution of drug-resistant phenotypes among different specimens.Depending on the source of the specimen, the clinicians can select appropriate antibiotics for relevant treatment, which can provide more specific theoretical basis for clinical experience in drug selection.

Key words： Escherichia coli Resistance Phenotype Antibiotic

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	JIANG Su-xiang
	ZHENG Gang-sen
	LIAN Ming-jian
	CHEN Mei-jun

Cite this article:

JIANG Su-xiang,ZHENG Gang-sen,LIAN Ming-jian, et al. Investigation analysis of drug-resistant phenotypes of Escherichia coli clinically isolated from our hospital in 2016[J]. 中国当代医药, 2020, 27(12): 147-150转167.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2020/V27/I12/147

[1]	Yong D，Toleman MA，Giske CG，et al.Characterization of a new metallo-beta-lactamase gene，bla （NDM-1），and a novel eryehromycin esterase gene carried on a unique genetic structure in Klebsiella pneunoniae sequence type 14 from India[J].Antimicrob Agents Chemother，2009，53（12）：5046-5054.
[2]	孙鹏飞，夏文颖，王钰，等.ST131型产NDM-1型碳青霉烯酶大肠埃希菌的耐药机制研究[J].临床检验杂志，2018，36（9）：655-659.
[3]	陈韩，陈思思，余方友.2011年至2015年耐亚胺培南大肠埃希菌临床分离的耐药性分析[J].中国临床药理学杂志，2017，33（2）：232-234.
[4]	刘周，李昕，储雯雯，等.碳青霉烯耐药肠杆菌科细菌临床分布及耐药特征分析[J].安徽医学，2018，39（3）：274-277.
[5]	M100-S25.Performance standards for antimicrobial susceptibility testing[S].Twenty-five informational supplement，CLSI，2015，35（3）：1-236.
[6]	胡付品，朱德妹，复，等.2014年CHINET 中国细菌耐药性监测[J].中国感染与化疗杂志，2015，15（5）：401-410.
[7]	《2015年全国细菌耐药监测报告》.http：//www.carss.cn/Report/Details?aId=282.
[8]	梅艳芳，刘盼盼，王莲慧，等.新德里金属酶β-内酰胺酶亚型在碳青霉烯类耐药肠杆菌中分布及分子流行病学研究[J].中华医院感染学杂志，2017，27（2）：241-246.
[9]	张艳君，秦琴，李虎，等.耐碳青霉烯类肠杆菌科细菌的分布特点与耐药性分析[J].中华医院感染学杂志，2016，26（2）：245-247.
[10]	刘芳，周玉宝，王新刚，等.胆道感染病原菌分布与耐药性分析[J].中华医院感染学杂志，2015，25（17）：3899-3905.
[11]	蔡鲜，李妍淳，李金，等.腹腔分离标本病原体构成及耐药性分析[J].中国抗生素杂志，2016，41（10）：782-787.
[12]	张艳君，马秀珍，秦琴，等.血流感染病原菌的分布与耐药性分析[J].中国感染与化疗杂志，2017，17（3）：314-320.
[13]	李海英，王金波，王华，等.近3年分离大肠埃希菌耐药性的分析[J].中国抗生素杂志，2018，43（5）：620-623.
[14]	孙景熙，王福斌，陈剑明，等.2012年-2016年医院大肠埃希菌分布特征及耐药性分析[J].中国卫生检验杂志，2019，29（6）：669-672.
[15]	展冠军，朱国龙，戴真南，等.临床不同标本及不同科室的大肠埃希菌耐药性分析[J].中国抗生素杂志，2018，43（6）：734-738.
[16]	潘玫，陈山，李稳，等.大肠埃希菌耐药特征及质粒介导喹诺酮耐药基因分布[J].国感染与化疗杂志，2016，16（1）：15-19.
[17]	石莹，刘亚男，李锐，等.大肠埃希菌对碳青霉烯类及喹诺酮类抗菌药物的耐药性分析[J].中华医院感染学杂志，2017，27（21）：4808-4810，4814.
[18]	HU F，O′HARA JA，RIVERA JI，et al.Molecular features of community-associated extended-spectrum-β-lactamase-producing Escherichia coli strains in the United States[J].Antimicrob Agents Chemother，2014，58（11）：6953-6957.
[19]	毛炜，费林立，陈柯婷，等.2016～2017年诸暨地区产超广谱β 内酰胺酶大肠埃希菌和肺炎克雷伯菌检出及药敏情况[J].实用预防医学，2019，26（4）：481-484.
[20]	赵鑫，程勇，杨海帆，等.泌尿系患者感染大肠埃希菌的耐药基因分布特征[J].中国病原生物学杂志，2019，14（4）：468-472.
[21]	闫妹姝，陶晓明，华正祥，等.产超广谱β-内酰胺酶大肠埃希菌临床分布及耐药性分析[J].中国中西医结合外科杂志，2018，24（5）：609-612.
[22]	罗瑜，黄永茂，林雁，等.大肠埃希菌耐多药与产超广谱β-内酰胺酶关系的研究[J].西南军医，2018，20（3）：315-318.